A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma

NCT00788060 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Everolimus (RAD001)
DRUG: Sunitinib (Sutent)

Sponsor

Daniel George, MD

Collaborators

[object Object]
[object Object]